REVENTING AND MANAGING CARdiovascular disease (CVD) presents a challenge for health care and public health. 1,2 Nonmodifiable risk factors include increasing age, male sex, and heredity. Modifiable risk factors include smoking, hypertension, dyslipidemia, obesity, physical inactivity, and diabetes. [3][4][5] Among men, the annual rate of initial CVD events increases from 3 to 74 per 1000 from ages 35 to 44 years to ages 85 to 94 years, respectively. Similar increases occur among women a decade later. 6 Biomarkers (eg, C-reactive protein) have been combined with traditional risk factors to predict CVD events, 7 and molecular markers hold further promise. In 2007, genome-wide association studies on CVD identified a series of associated singlenucleotide polymorphisms (SNPs) in an intergenic region of chromosome 9p21, near the CDKN2A (NM_000077) and CDKN2B (NM_004936) genes. 8,9 Currently, no comprehensive compilation of the 9p21 literature uses formal methods to estimate the strength of the association with heart disease (eg, effect size, heterogeneity, publication bias, credibility of cumulative evidence) and examine clinical utility. This analysis is part of a targeted systematic review on existing cardiogenomic panels that in-cluded 28 genes in addition to the 9p21 SNPs. That review was commissioned by the Evaluation of Genomic Applica-